Utah Medical Products, Inc. develops, manufactures, and markets specialty medical devices focused on critical care, gynecology, neonatology, obstetrics, surgery, and urology. The company’s product portfolio includes intrauterine pressure catheters, fetal monitoring accessories, uterine balloon tamponade systems, cervical ripening catheters, and pelvic floor stimulation systems. Key brands include INTRAN PLUS, BT-Cath, CVX-Ripe, Abcorp, Bari-Belts, Nutri-Cath, OptiSpec, and the Filshie Clip System. The company also offers BioPharm HP-PRT sensors and the Veri-Test Sensor Verifier. Utah Medical Products serves hospitals, outpatient clinics, and physician offices in the United States and internationally, with direct sales operations in Canada, the United Kingdom, France, Ireland, Australia, and New Zealand. The company manufactures components and finished devices on a subcontract basis for other medical device companies. Subsidiaries include Utah Medical Products Ltd., Femcare Holdings Ltd., and Utah Medical Products Canada Ltd. Founded in 1978, the company integrates engineering disciplines in electronics, software, mechanical assembly, and materials to produce differentiated devices for patient safety and clinical outcomes.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Medical Devices Homepage utahmed.com
Sector Healthcare IR page utahmed.com/investor-relations.html
Tags
obstetrics, neonatology, gynecology, urology, fetal monitoring, pelvic floor stimulation, cervical ripening, uterine tamponade, enteral feeding, biopharma sensors, INTRAN PLUS, BT-Cath, CVX-Ripe, Abcorp, Bari-Belts, Bari-Bands, Nutri-Cath, OptiSpec, Filshie Clip System, Liberty Pelvic Floor Stimulation System, BioPharm HP-PRT Sensors, Veri-Test Sensor Verifier, Utah Medical Products Ltd., Femcare Holdings Ltd., Femcare Australia Pty Ltd, Utah Medical Products Canada Ltd., Columbia Medical Inc., Gesco International, Abcorp Inc.
Press page —

Metrics

Valuation  
Market cap $ 211.931M
Market cap (USD) $ 211.931M
P/E 19.99
PEG —
P/BV 1.72
P/S 6.07
P/OCF 18.48
P/FCF 19.51
Dividend yield 0.03%
Turnover / mcap —
Returns  
ROE 9.5%
ROI 33.5%
ROIC 27.0%
Profit margin 29.3%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -11.8%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999 FY 1998
Revenue 38.52M 40.903M 50.224M 52.281M 49.054M 42.178M 46.904M 41.998M 41.414M 39.298M 40.157M 41.278M 40.493M 41.552M 37.86M 25.121M 25.916M 27.782M 28.502M 28.753M 27.692M — 27.137M — 26.954M — 29.444M 27.677M
Net profit 11.286M 13.874M 16.635M 16.473M 14.788M 10.798M 14.727M 18.555M 8.505M 12.128M 11.843M 11.378M 11.406M 10.169M 7.414M 6.014M 6.258M 7.205M 7.905M 8.168M 7.547M 10.22M 20.761M 7.165M 5.934M 5.373M 5.468M 4.858M
Free cash flow 14.321M 14.601M 21.642M 20.338M 20.651M 19.277M 16.516M 16.432M 15.311M 11.235M 13.625M 14.277M 11.97M 13.309M 11.118M 5.625M — — — — — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999 FY 1998
Share price 55.96 61.47 84.22 100.53 100 84.3 107.9 83.07 81.39 72.75 58.54 60.05 57.16 36.13 25.76 28 29.5 30 30 30.25 — — — — — — — —
Price performance 12m -0.09 -0.27 -0.16 0.01 0.19 -0.22 0.3 0.02 0.12 0.24 -0.03 0.05 0.58 0.4 -0.08 -0.05 -0.02 0 -0.01 — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 3.21M 3.62M 3.96M 4.74M 4.1M 5.13M 5.54M 3.39M 4.09M 3.52M
↳ YoY growth -29.6% +12.8% +9.2% +19.9% -13.5% +25.0% +7.9% -38.8% +20.7% -14.0%
↳ 5y CAGR -7.5% -3.6% -1.8% +0.2% -2.1% +9.8% +8.9% -3.0% -2.9% -3.0%
Borrowings, non-current (USD) — — — — — — — 295,000 282,000 225,000
Lease liabilities (USD) — — 0.00 414,000 376,000 448,000 395,000 342,000 338,000 286,000
Cash and deposits (USD) 26.3M 39.9M 51.1M 42.8M 51.6M 61M 75.1M 92.9M 83M 85.8M
Intangible assets (USD) 18.3M 17.8M 14.8M 30.2M 24M 17.3M 10.4M 4.95M 2.87M 840,000
Right-of-use assets (USD) — — 0.00 414,000 377,000 449,000 395,000 342,000 338,000 286,000
Net debt (borrowings + leases - cash) (USD) — — — — — — — -92.6M -82.4M -85.2M
Cash flow detail
Operating cash flow (USD) 14.5M 16.9M 16.8M 17.1M 20.1M 21.2M 21.1M 22.3M 14.8M 14.7M
Purchases of property, plant and equipment (USD) -3.29M -1.6M -402,000 -540,000 -860,000 -552,000 -809,000 -639,000 -230,000 -371,000
Purchases of intangible assets (USD) -9,000 0.00 0.00 -21M 0.00 0.00 -9,000 0.00 -5,000 0.00
Change in receivables (cash effect) (USD) 295,000 -242,000 496,000 -738,000 617,000 -1.09M -511,000 2.27M -835,000 338,000
Change in inventories (cash effect) (USD) -360,000 -467,000 244,000 -1.69M 924,000 -485,000 -2.35M -670,000 587,000 1.2M
Change in payables (cash effect) (USD) 286,000 9,000 52,000 114,000 -308,000 -23,000 464,000 -456,000 -73,000 211,000
Dividends paid (cash effect) (USD) -3.92M -2.96M -4.03M -4.11M -4.12M -11.5M -3.16M -4.28M -4.26M -3.98M
Share buybacks (cash effect) (USD) — 0.00 -1.21M -398,000 -6.98M 0.00 -2.5M 0.00 -20M -8.36M
Interest paid (cash effect) (USD) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Income taxes paid (cash effect) (USD) -4.85M -5.15M -4.85M -5.3M -3.19M -4.62M -4.97M -4.83M -4.64M -4M
Share-based compensation (USD) 92,000 129,000 64,000 113,000 160,000 166,000 183,000 225,000 256,000 373,000
Operating cash flow before change in receivables (USD) 14.2M 17.2M 16.3M 17.8M 19.5M 22.3M 21.7M 20M 15.7M 14.4M
Free cash flow (OCF - PPE - intangibles) (USD) 11.2M 15.3M 16.4M -4.48M 19.3M 20.7M 20.3M 21.6M 14.6M 14.3M
Income detail
Research and development expense (USD) 475,000 447,000 454,000 483,000 486,000 526,000 493,000 560,000 813,000 668,000
↳ 5y CAGR -1.7% -4.5% +1.0% -1.4% +2.1% +2.0% +4.3% +11.0% +6.6%
Total comprehensive income (USD) 5.84M 12.4M 15.6M 16.2M 12.3M 14M 13.5M 18M 12.6M 13.8M
Comprehensive income to owners (USD) 5.84M 12.4M 15.6M 16.2M 12.3M 14M 13.5M 18M 12.6M 13.8M
Provision for credit losses (USD) 0.00 4,000 20,000 14,000 -5,000 24,000 30,000 -33,000 -4,000 367,000
Credit cost ratio (credit losses / average receivables) (%) 0.0% 0.1% 0.5% 0.3% 0.1% 0.5% 0.6% 0.7% 0.1% 9.6%
Reported Mar 8, 2017 Mar 16, 2020 Mar 16, 2020 Mar 16, 2020 Mar 26, 2021 Mar 25, 2022 Mar 27, 2023 Mar 26, 2025 Mar 26, 2025 Mar 27, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Utah Medical Products, Inc. Increases Quarterly Dividend Bull 2 Bear 0 Capital return

Contact: Brian KoopmanNovember 3, 2026

(801) 566-1200

Salt Lake City, Utah - Utah Medical Products, Inc. (Nasdaq: UTMD) announces that its Board of Directors has approved a quarterly cash dividend of thirty-one and one-half cents ($.315) per share of common stock payable on January 5, 2027 to stockholders of record at the close of business on December 17, 2026. This is a 1.6% increase over the prior regular quarterly cash dividend.

Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal long-term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD’s website at www.utahmed.com.

UTMD-PR110326.pdf Bull 3 Bear 0 Capital return

UTAH MEDICAL PRODUCTS, INC. 7043 South 300 West Midvale, Utah 84047 Telephone: 801-566-1200 FAX: 801-566-2062 Nasdaq Symbol: UTMD www.utahmed.com

PRESS RELEASE Utah Medical Products, Inc. Increases Quarterly Dividend

UTMD-PR102926.pdf Bull 0 Bear 0 Routine

UTAH MEDICAL PRODUCTS, INC. 7043 South 300 West Midvale, Utah 84047 Telephone: 801-566-1200 FAX: 801-566-7305 Nasdaq Symbol: UTMD www.utahmed.com

PRESS RELEASE Utah Medical Products, Inc. Reports Corrected Results of Tender Offer

Prompts

Utah Medical Products, Inc. (ticker UTMD), listed in United States.

ETFs Holding Utah Medical Products, Inc.

ETF Weight in ETF Shares Market value As of
SCDS 0.22% 277 $ 19.95K Nov 17, 2026
SQLV 0.21% 856 $ 59.047K Jun 30, 2026
SFGV 0.03% 4,061 $ 290K Nov 18, 2026
AVSC 0.01% 5,735 $ 414.985K Nov 16, 2026
MSSM 0.00% 72 $ 5,121.36 Aug 31, 2026
DFSV 0.00% 2,205 $ 162.354K Nov 12, 2026
DFAU 0.00% 306 $ 22.497K Nov 12, 2026
DFAC 0.00% 1,342 $ 98.811K Nov 12, 2026